CO6410311A2 - Variantes de union a anti-albúmina de suero mejoradas - Google Patents

Variantes de union a anti-albúmina de suero mejoradas

Info

Publication number
CO6410311A2
CO6410311A2 CO11111121A CO11111121A CO6410311A2 CO 6410311 A2 CO6410311 A2 CO 6410311A2 CO 11111121 A CO11111121 A CO 11111121A CO 11111121 A CO11111121 A CO 11111121A CO 6410311 A2 CO6410311 A2 CO 6410311A2
Authority
CO
Colombia
Prior art keywords
improved
albúmina
serero
union
variations
Prior art date
Application number
CO11111121A
Other languages
English (en)
Inventor
Angeles Elena De
Carolyn Enever
Christopher J Plummer
Haiqun Liu
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6410311A2 publication Critical patent/CO6410311A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a variantes mejoradas del dominfo variable sencillo de inmunoglobulina anti-albúmina de suero DOM7h-11, así como a ligandos y conjugados de fármacos que comprenden dichas variantes, composiciones, ácido nucleicos, vectores y huéspedes.
CO11111121A 2009-02-19 2011-08-30 Variantes de union a anti-albúmina de suero mejoradas CO6410311A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16398709P 2009-03-27 2009-03-27
US24713609P 2009-09-30 2009-09-30

Publications (1)

Publication Number Publication Date
CO6410311A2 true CO6410311A2 (es) 2012-03-30

Family

ID=42634270

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11111121A CO6410311A2 (es) 2009-02-19 2011-08-30 Variantes de union a anti-albúmina de suero mejoradas

Country Status (25)

Country Link
US (3) US9534043B2 (es)
EP (3) EP3330287B1 (es)
JP (2) JP5759391B2 (es)
KR (1) KR101819754B1 (es)
CN (1) CN102405233B (es)
AR (1) AR075505A1 (es)
AU (1) AU2010215482B2 (es)
BR (1) BRPI1013341B1 (es)
CA (2) CA3079184A1 (es)
CL (1) CL2011002025A1 (es)
CO (1) CO6410311A2 (es)
DO (1) DOP2011000266A (es)
EA (1) EA028178B1 (es)
ES (2) ES2774192T3 (es)
HK (1) HK1247944A1 (es)
IL (1) IL214480A0 (es)
MA (1) MA33051B1 (es)
MX (1) MX2011008749A (es)
NZ (1) NZ595242A (es)
PE (1) PE20120001A1 (es)
SG (1) SG173489A1 (es)
TW (1) TW201042039A (es)
UY (1) UY32450A (es)
WO (1) WO2010094723A2 (es)
ZA (1) ZA201105657B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021146B1 (ru) * 2009-03-27 2015-04-30 Глаксо Груп Лимитед Продукты слияния и конъюгаты лекарственных средств
WO2011008814A2 (en) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
US20120276098A1 (en) * 2009-09-30 2012-11-01 Bruce Hamilton Drug fusions and conjugates with extended half life
AR078763A1 (es) * 2009-10-27 2011-11-30 Glaxo Group Ltd Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas
AU2011254559B2 (en) * 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
JP2013538566A (ja) * 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
CN103459422A (zh) * 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
JP2014501515A (ja) 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
WO2012104227A1 (en) 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
CN115837014A (zh) 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
JP7130678B2 (ja) 2017-06-05 2022-09-05 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｈｓａ抗体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
SI1517921T1 (sl) 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
DE602005023291D1 (de) 2004-03-24 2010-10-14 Domantis Ltd Universelles signalpeptid gas1
EP1784427A2 (en) 2004-06-01 2007-05-16 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
NZ555464A (en) 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
JP2009518025A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド 細胞表面標的に対して結合特異性を有する二重特異性リガンドおよびその使用方法
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2010060486A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Ligands that bind il-13
UY32452A (es) 2009-02-19 2010-09-30 Glaxo Group Ltd Variantes de unión a anti-albúmina de suero mejoradas
AU2010215479B2 (en) * 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
WO2011006914A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
US20120276098A1 (en) * 2009-09-30 2012-11-01 Bruce Hamilton Drug fusions and conjugates with extended half life
CA2796932A1 (en) * 2010-04-21 2011-10-27 Glaxo Group Limited Binding domains

Also Published As

Publication number Publication date
JP2012517820A (ja) 2012-08-09
EP3330287A1 (en) 2018-06-06
ES2655071T3 (es) 2018-02-16
MA33051B1 (fr) 2012-02-01
TW201042039A (en) 2010-12-01
EP3656788A3 (en) 2020-07-29
US10696738B2 (en) 2020-06-30
BRPI1013341B1 (pt) 2021-09-08
US9534043B2 (en) 2017-01-03
JP5759391B2 (ja) 2015-08-05
CN102405233A (zh) 2012-04-04
UY32450A (es) 2010-09-30
JP6100315B2 (ja) 2017-03-22
US20170298121A1 (en) 2017-10-19
CA2767752A1 (en) 2010-08-26
KR101819754B1 (ko) 2018-01-18
SG173489A1 (en) 2011-09-29
CN102405233B (zh) 2014-11-26
KR20110127223A (ko) 2011-11-24
PE20120001A1 (es) 2012-02-12
EP3656788A2 (en) 2020-05-27
MX2011008749A (es) 2011-09-06
WO2010094723A2 (en) 2010-08-26
AU2010215482A1 (en) 2011-08-25
JP2015204831A (ja) 2015-11-19
EP2398826A2 (en) 2011-12-28
HK1247944A1 (zh) 2018-10-05
NZ595242A (en) 2013-11-29
EA201171068A1 (ru) 2012-02-28
ES2774192T3 (es) 2020-07-17
AU2010215482B2 (en) 2014-02-13
CA3079184A1 (en) 2010-08-26
DOP2011000266A (es) 2011-12-31
BRPI1013341A2 (pt) 2016-10-11
IL214480A0 (en) 2011-09-27
EP3330287B1 (en) 2019-12-18
AR075505A1 (es) 2011-04-06
US20110305696A1 (en) 2011-12-15
CA2767752C (en) 2020-07-07
US20200283512A1 (en) 2020-09-10
EP2398826B1 (en) 2017-10-25
WO2010094723A3 (en) 2011-04-21
ZA201105657B (en) 2012-04-25
CL2011002025A1 (es) 2012-04-09
EA028178B1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
DOP2011000269A (es) Variantes de union a anti-albumina de suero mejoradas
CO6410311A2 (es) Variantes de union a anti-albúmina de suero mejoradas
IN2012DN00640A (es)
CY1121349T1 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
CY1120327T1 (el) Συζευγματα αντισωματος-πυρρολοβενζοδιαζεπινης
EA201992456A2 (ru) Самостабилизирующиеся линкерные конъюгаты
CY1119287T1 (el) Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης-αντι-her2
CY1119567T1 (el) Θεραπευτικα πεπτιδια
EA201291009A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
EA201171325A1 (ru) Нуклеиновые кислоты, связывающиеся с гепсидином
CR20180393A (es) Conjugados de enzimas terapéuticas
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
EA201101165A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
CR20130266A (es) PROTEÍNAS DE UNIÓN AL TNF-a
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
EA201791359A1 (ru) Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина
WO2011123820A3 (en) Single isomeric conjugates of rhodamine dyes
EA201390940A1 (ru) Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком
EA201291065A1 (ru) Антитела против vla-4
TR201903403T4 (tr) İmmünoglobulin preparatı.
LT2013016A (lt) Aktyvuotos-potencijuotos formos antikūno poveikio padidinimo būdas
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains

Legal Events

Date Code Title Description
FC Application refused